Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | HTT | P42858 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamine SCHEMBL31418669 | 0.97 | MEN1 (0.53) | MEN1KMT2AKDM4EHTTSMN1; SMN2 | |
| SCHEMBL24074659 | 0.85 | ALDH1A1 (0.57) | MEN1KMT2AKDM4EHTTSMN1; SMN2 | |
| SCHEMBL3689460 | 0.84 | KDM4E (0.46) | MEN1KMT2AKDM4EHTTSMN1; SMN2 | |
| SCHEMBL24440339 | 0.83 | KDM4E (0.48) | MEN1KMT2AKDM4EHTTSMN1; SMN2 | |
| SCHEMBL29266193 | 0.83 | ALDH1A1 (0.47) | MEN1KMT2AKDM4EHTTSMN1; SMN2 | |
| SCHEMBL27592816 | 0.83 | KDM4E (0.46) | MEN1KMT2AKDM4EHTTSMN1; SMN2 | |
| SCHEMBL1319623 | 0.82 | GABRA1 (0.58) | MEN1KMT2AKDM4EHTTSMN1; SMN2 | |
| SCHEMBL680147 | 0.82 | GABRA1 (0.61) | MEN1KMT2AKDM4EHTTSMN1; SMN2 | |
| SCHEMBL9755152 | 0.82 | LMNA (0.53) | KMT2AKDM4EHTTMAPTLMNA | |
| SCHEMBL28452243 | 0.82 | GABRA1 (0.57) | KMT2AKDM4EHTTGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190248958-A1 | PREPARATION METHOD OF OLIGOMER ADDITIVE, OLIGOMER ADDITIVE, AND LITHIUM BATTERY | NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (TW) | 2019-08-15 | — | — | US | disclosed |
| WO-2005110981-A1 | AMINOALCOHOL DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | WO | disclosed |
| EP-1027043-B1 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-11-10 | — | — | EP | disclosed |
| EP-1027043-A4 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2002-02-20 | — | — | EP | disclosed |
| EP-1027043-A1 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | Bristol-Myers Squibb Company (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6060506-A | FOR TREATMENT OF SLEEP DISORDERS, CIRCADIAN RHYTHM DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
| US-5981571-A | USEFUL AS MELATONERGIC AGENTS IN THE TREATMENT OF SLEEP DISORDERS, SEASONAL DEPRESSION, SHIFTS IN CIRCADIAN CYCLES, MELANCHOLIA, STRESS, APPETITE REGULATION, BENIGN PROSTATIC HYPERPLASIA AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-11-09 | — | — | US | disclosed |
| US-5856529-A | ADJUSTMENT OF NERVOUS SYSTEM, ENDOCRINE FUNCTION; REPRODUCTION, BODY WEIGHT AND METABOLISM | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-01-05 | — | — | US | disclosed |
| WO-1998025606-A1 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5602277-A | Substituted benzene derivatives useful as neuraminidase inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-02-11 | — | — | US | disclosed |
| WO-1996030329-A1 | SUBSTITUTED BENZENE DERIVATIVES USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INCORPORATED (US) | 1996-10-03 | — | — | WO | disclosed |
| US-5409952-A | Anticancer agents | ADIR ET COMPAGNIE (FR) | 1995-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248958-A1 | PREPARATION METHOD OF OLIGOMER ADDITIVE, OLIGOMER ADDITIVE, AND LITHIUM BATTERY | PCNA, SCO2, PARG | MEN1 3606/4885KMT2A 2205/4885KDM4E 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.